Member Info for Fredd1eboy

https://www.britishbulls.com/m/SignalPage.aspx?lang=en&Ticker=VAL.L

...and cough £35k for the privilege !!

...to all.....didn't last long.
I'm only posting once as it's Saturday and no business activity.
What I really don't understand is the constant negativity from a few.....I stress negativity....it's as if they have a Valirx death wish....clearly they are not invested as no plan is presented...just slagging off.... personally I believe what Valirx has informed us....and will give them time to deliver....or not.... If they deliver....the SP will probably take off.....if they don't it's curtains....We shall see in the fullness of time!
As I have mentioned previously....let's be civil in reply...Wont post again this weekend. Best wishes. Freddie

Agreed Valju. ...Best wishes. Freddie

Excuse grammer but you get my drift

I'm fully aware of the bigger picture. I was just posting facts in the state of Apple. Guess we all need to pay more attention rtmather than keep kicking soft targets....is those who cannot reply back

Bit Dom and gloom aren't you roses...Apple remains hugely profitable and is sitting on $237bn in cash. In November the company announced record sales and profits but iPhone sales were flat

https://www.washingtonpost.com/business/bristol-myers-squibb-to-buy-celgene-in-a-cash-and-stock-deal-worth-74-billion/2019/01/03/852d7d4e-0f50-11e9-8f0c-6f878a26288a_story.html

Hi Adam...Guess it's because he is the most recent to increase his holdings....as we don't get much news from other investors and we do have a significant amount of very small investors...

Thanks mathproof....that could very well explain the inconsistency. Best wishes. Freddie

Hi Rightback.....yes I think you're right as I too cannot reconcile the numbers on the RNS for any other reasons

Thanks for reviewing noise. It's all beyond me...but China/FDA approval did sound interesting. Worth keeping an eye on...thanks again

Agreed Valju.....the mm's don't appear to credit investors with any savvy at all...

Understood Noise but isn't Resperidone the base drug for Suzie's line and, mindful of Resperidone track record for treating mental disorders, I thought the positive ala... "agreement with the FDA to waive all paediatric clinical studies"....may be beneficial to Valiseek cancer treatment line....or am I just barking up the wrong tree as it's probably irrelevant...or!

Probably irrelevant ..but maybe.
BRIEF—Luye Pharma updates on risperidone NDA
31-12-2018 Comments (0)Print
China’s Luye Pharma today announced that it has entered the final stage of New Drug Application (NDA) submissions for the innovative drug, risperidone extended release microspheres for injection (LY03004), after previous positive pre-NDA meeting with the US Food and Drug Administration and subsequent related procedures.

Luye had previously requested an NDA number for LY03004 and received a pre-assigned NDA application number (212849) from the FDA in 2018.

The submission dossier for LY03004 is completed and being published in eCTD format according to FDA requirements.

Luye successfully reached an agreement with the FDA to waive all paediatric clinical studies of LY03004, and obtained FDA's approval of using Rykindoas LY03004's brand name for the treatment of schizophrenia or schizoaffective disorder.

The company expects LY03004 will be launched in the USA and China markets by the end of 2019.

ChinaCNS DiseasesFocus OnLuye PharmaLY03004NeurologicalPharmaceuticalRegulationRisperidoneRykindoUS FDAUSA
MORE ON THIS STORY

China’s Luye Pharma expands collaboration with Elpis
07-06-2018

Luye Pharma inks $538 million licensing deal for Seroquel
07-05-2018

OTHER STORIES OF INTEREST

Antengene raises $120 million in Series B financing
02-01-2019

Heron Therapeutics' NDA for HTX-011 accepted for Priority Review by FDA
01-01-2019

Zai Lab launches Optune in Hong Kong for patients with GMB
01-01-2019

RELATED NEWS FROM THE WEB

Nivolumab Is China's First Approved Immuno-Oncology Drug
28-06-2018

CEO ambition: top generic pharmaceutical maker eyes Asian market
09-05-2018

Chinese investors pump new dollars into Maryland's pharmaceutical industry
05-03-2018

RELATED REPORT
Gastric and Gastroesophageal Junction Adenocarcinoma - China Drug Forecast and Market Analysis to 2024

£4,995.00
ADD TO BASKET
RELATED COMPANIES

Luye Pharma
RELATED DRUGS

Risperidone
Twitter Facebook LinkedIn Google+
Luye Pharma, LY03004, Risperidone, Rykindo, NDA, Schizophrenia
MORE ON THIS STORY...
Previous
China’s Luye Pharma expands collaboration with Elpis
07-06-2018

Next
Your Comments
Login to add a comment

There are no comments yet. Be the first and leave a response!

EDITOR'S PICKSMOST READ
1 OF 5
Russia expands list of vital drugs, including latest drugs from global majors

Russia expands list of vital drugs, including latest drugs from global majors

China's NMPA approves Innovent's anti-PD-1 antibody Tyvyt

China's NMPA approves Innovent's anti-PD-1 antibody Tyvyt

Stricter checks for generic medicines in India

Stricter checks for generic medicines in India

India needs new initiatives to tackle cancer care

India needs new initiatives to tackle cancer care

InventisBio and Betta Pharma to co-develop novel NSCLC drug

InventisBio and Betta Pharma to co-develop novel NSCLC

We live in hope surprised.... Could 2019 be our year when Reneuron stands on is own revenue generating income. Best wishes and happy prosperous new. Fred

....a recommendation to all your recent posts.....Best wishes. Fred

And you too Jonhboy and Kaneonaim and best of luck for 2019.

Too true Valju..... wishing you a happy Christmas and a prosperous new year

A very merry Christmas to you too Chelsea along with all others on this site. Yes ...let's all be more sensitive to others views from hereon...also wishing you improved health for 2019
Best wishes. Fred